Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Merck Sharp & Dohme LLC
BioNTech SE
Aurigene Discovery Technologies Limited
Aurigene Discovery Technologies Limited
Merck Sharp & Dohme LLC
Sichuan Baili Pharmaceutical Co., Ltd.
Sichuan Baili Pharmaceutical Co., Ltd.
BioNTech SE
Bayer
Sichuan Baili Pharmaceutical Co., Ltd.
Bristol-Myers Squibb
Bayer
Eli Lilly and Company
Pheon Therapeutics
AstraZeneca
Daiichi Sankyo
Eli Lilly and Company
Pfizer
Pfizer
Teclison Ltd.
InSightec
AstraZeneca
AstraZeneca
AstraZeneca
Merck Sharp & Dohme LLC
Amgen
Bristol-Myers Squibb
ArriVent BioPharma, Inc.
Kivu Bioscience Inc.
Achieve Life Sciences
ImmunityBio, Inc.
Iovance Biotherapeutics, Inc.
Tango Therapeutics, Inc.
Instil Bio
BeOne Medicines
AstraZeneca
Hummingbird Bioscience
Amgen
BeOne Medicines
Boehringer Ingelheim
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Bristol-Myers Squibb
Exelixis
BeOne Medicines
BioNTech SE
ImmunityBio, Inc.
BioNTech SE
BicycleTx Limited
Bristol-Myers Squibb